These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8840180)

  • 1. Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon.
    Bon GG; Verheijen RH; Zuetenhorst JM; van Kamp GJ; Verstraeten AA; Kenemans P
    Gynecol Obstet Invest; 1996; 42(1):58-62. PubMed ID: 8840180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
    Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
    Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
    Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
    Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
    Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
    Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sensitivity and specificity of CEA, Ca 15-3 and MCA levels in visceral breast carcinoma metastasis].
    Delbrück H; Hagen-Aukamp C; Braun G
    Strahlenther Onkol; 1990 Jul; 166(7):457-9. PubMed ID: 2200152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of a second generation CA 15-3 antibody to detect adenocarcinoma in body cavity effusions.
    Zimmerman RL; Fogt F; Goonewardene S
    Cancer; 2000 Aug; 90(4):230-4. PubMed ID: 10966563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.
    Yedema CA; Kenemans P; Wobbes T; Thomas CM; Bon GG; Mulder C; Voorhorst FJ; Verstraeten AA; van Kamp GJ; Hilgers J
    Tumour Biol; 1992; 13(1-2):18-26. PubMed ID: 1589694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass.
    Schutter EM; Davelaar EM; van Kamp GJ; Verstraeten RA; Kenemans P; Verheijen RH
    Am J Obstet Gynecol; 2002 Aug; 187(2):385-92. PubMed ID: 12193930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3.
    Miserez AR; Günes I; Müller-Brand J; Walther E; Fridrich R; Mäcke H
    Eur J Cancer; 1991; 27(2):126-31. PubMed ID: 1827273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCA in patients with breast cancer: correlation with CEA and CA15-3.
    Molina R; Filella X; Mengual P; Prats M; Zanon G; Daniels M; Ballesta AM
    Int J Biol Markers; 1990; 5(1):14-21. PubMed ID: 2230347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a common antigen of colorectal and mucinous ovarian tumors, COTA.
    Pant KD; Zamora PO; Rhodes BA; Sachatello CR; Hagihara PF; Griffen WO; van Nagell JR; Fulks R; Ram MD
    Tumour Biol; 1984; 5(5):243-54. PubMed ID: 6442455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
    Kobayashi H; Terao T; Kawashima Y
    J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of M43: a novel cancer-associated mucin epitope.
    Goodgame R; Kiefe C; Rose E; Sutton F; Brown J; Alpert E
    Cancer Res; 1993 Jun; 53(12):2803-9. PubMed ID: 7684947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
    Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of MCA, CA 15-3, CEA and CA-125 for discrimination between metastatic breast cancer and adenocarcinoma of other primary sites.
    De Wit R; Hoek FJ; Bakker PJ; Veenhof CH
    J Intern Med; 1991 May; 229(5):463-6. PubMed ID: 2040873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.